The WN1316-treated groups also showed a trend towards sustained motor performance in the balance beam test and a higher spontaneous motor activity in both cage activity and rearing performance than vehicle-treated group in a late symptomatic stage ( Figure S5B, E and F ).
← all excerpts
A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model.
1
—
—